Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages 165-173

  Azuara, Daniel ^a   Rodriguez Moranta, Francisco ^b   De Oca, Javier ^b   Sanjuan, Xavier ^b   Guardiola, Jordi ^b   Lobaton, Triana ^b   Wang, Alex ^a   Boadas, Jaume ^c   Piqueras, Marta ^c   Monfort, David ^c   Galter, Sara ^c   Esteller, Manel ^a   Moreno, Victor ^a   Capellá, Gabriel ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DE TERRASSA   (Spain)

Author keywords

Colorectal cancer diagnosis; IBD associated neoplasia; Methylation panel; Methylation specific melting curve analysis

Indexed keywords

DNA; HEPARIN SULFATE DEXTRO GLUCOSAMINYL3 O SULFOTRANSFERASE 2; MEMBRANE PROTEIN; SLIT2 PROTEIN; SULFOTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA2; TRANSMEMBRANE PROTEIN WITH EPIDERMAL GRPWTH FACTOR LIKE AND TWO FOLLISTATIN LIKE DOMAIN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DNA METHYLATION; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; TRANSVERSE COLON; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; DNA; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKERS, BIOLOGICAL;

EID: 84873407557     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22994     Document Type: Article

References (55)

1. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950-954.
2. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-1233.
3. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103:1444-1451.
4. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746-774, 774 e741-744, quiz e712-743.
5. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996;110:331-338.
6. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
7. Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998;115:1079-1083.
8. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
9. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880-888.
10. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-1816.
11. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000;47:57-70.
12. Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis. J Clin Gastroenterol. 2001;32:99-105.
13. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol. 2004;287:G7-17.
14. Goel GA, Kandiel A, Achkar JP, et al. Molecular pathways underlying IBDassociated colorectal neoplasia: therapeutic implications. Am J Gastroenterol. 2011;106:719-730.
15. Risques RA, Rabinovitch PS, Brentnall TA. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr Opin Gastroenterol. 2006;22:382-390.
16. Schulmann K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology. 2005; 129:74-85.
17. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333-3337.
18. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000;60:4864-4868.
19. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573-3577.
20. Sato F, Harpaz N, Shibata D, et al. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 2002; 62:1148-1151.
21. Fujii S, Tominaga K, Kitajima K, et al. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut. 2005;54: 1287-1292.
22. Hsieh CJ, Klump B, Holzmann K, et al. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 1998;58:3942-3945.
23. Wang FY, Arisawa T, Tahara T, et al. Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology. 2008;55:62-65.
24. Kanai Y. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci. 2010;101:36-45.
25. Nakajima T, Enomoto S, Yamashita S, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol. 2010;45:37-44.
26. Lin Z, Hegarty J, Cappel J, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011;80:59-67.
27. Saito S, Kato J, Hiraoka S, et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis. 2011;17:1955-1965.
28. Puig P, Urgell E, Capella G, et al. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer. 2000;85:73-77.
29. Puig P, Urgell E, Capella G, et al. Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest. 1999;79:617-618.
30. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003;63:3560-3566.
31. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010;9:168-176.
32. Frigola J, Song J, Stirzaker C, et al. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38:540-549.
33. Wojdacz TK, Hansen LL. Reversal of PCR bias for improved sensitivity of the DNA methylation melting curve assay. BioTechniques. 2006;41: 274, 276, 278.
34. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010; 105:1610-1619.
35. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
36. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130:1030-1038.
37. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29:206-217.
38. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91: 854-862.
39. Belshaw NJ, Elliott GO, Williams EA, et al. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1495-1501.
40. Leung WK, To KF, Man EP, et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem. 2004;50:2179-2182.
41. Mayor R, Casadome L, Azuara D, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer. 2009; 100: 1534-1539.
42. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97:1107-1109.
43. Matsumura S, Oue N, Ito R, et al. The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis. Virchows Arch. 2003;443:518-523.
44. Sato F, Shibata D, Harpaz N, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002;62: 6820-6822.
45. Kim JC, Roh SA, Cho DH, et al. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anti-cancer Res. 2009;29:3115-3123.
46. Kouvidou C, Latoufis C, Lianou E, et al. Expression of Smad4 and TGFbeta2 in colorectal carcinoma. Anticancer Res. 2006;26:2901-2907.
47. Salzman SA, Mazza JJ, Burmester JK. Regulation of colony-stimulating factor-induced human myelopoiesis by transforming growth factor-beta isoforms. Cytokines Cell Mol Ther. 2002;7:31-36.
48. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factors-beta1,-beta2 and-beta3 in human colon carcinoma. Eur J Cancer. 2001;37:224-233.
49. Dallol A, Morton D, Maher ER, et al. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 2003;63:1054-1058.
50. Takahashi T, Shigematsu H, Shivapurkar N, et al. Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer. 2006;118:924-931.
51. Miyamoto K, Asada K, Fukutomi T, et al. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Onco-gene. 2003;22: 274-280.
52. Gonzalo V, Lozano JJ, Munoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PloS One. 2010; 5:e8777.
53. He Q, Chen HY, Bai EQ, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet. 2010;202:1-10.
54. Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007;132: 1254-1260.
55. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane proteinencoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci U S A. 2001;98:265-270.